Cingulate Shares Are Trading Lower. The Company Announced It Commenced Its Final FDA-required Study, Which Is a Food Effect Study, for CTx-1301 for the Treatment of Attention Deficit Hyperactivity Disorder.
Cingulate Shares Are Trading Lower. The Company Announced It Commenced Its Final FDA-required Study, Which Is a Food Effect Study, for CTx-1301 for the Treatment of Attention Deficit Hyperactivity Disorder.
金格股票交易下跌。公司宣佈已開始進行最後的FDA所要求的研究，即食物效應研究，用於治療注意力缺陷多動障礙。
Cingulate Shares Are Trading Lower. The Company Announced It Commenced Its Final FDA-required Study, Which Is a Food Effect Study, for CTx-1301 for the Treatment of Attention Deficit Hyperactivity Disorder.
Cingulate的股票交易價格走低。該公司宣佈已開始對治療注意力缺陷多動障礙的CTx-1301進行美國食品藥品管理局要求的最後一項研究，即食物效應研究。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。